

# Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia

Antonio F. Pardiñas, PhD; Sophie E. Smart, PhD; Isabella R. Willcocks, MSc; Peter A. Holmans, PhD; Charlotte A. Dennison, BSc; Amy J. Lynham, PhD; Sophie E. Legge, PhD; Bernhard T. Baune, MD, PhD; Tim B. Bigdeli, PhD; Murray J. Cairns, PhD; Aiden Corvin, MD, PhD; Ayman H. Fanous, MD; Josef Frank, PhD; Brian Kelly, MD, PhD; Andrew McQuillin, PhD; Ingrid Melle, MD, PhD; Preben B. Mortensen, DrMedSc; Bryan J. Mowry, MD; Carlos N. Pato, MD, PhD; Sathish Periyasamy, PhD; Marcella Rietschel, MD; Dan Rujescu, MD, PhD; Carmen Simonsen, PhD; David St Clair, PhD; Paul Tooney, PhD; Jing Qin Wu, PhD; Ole A. Andreassen, MD, PhD; Kaarina Kowalec, PhD; Patrick F. Sullivan, MD, PhD; Robin M. Murray, DSc; Michael J. Owen, PhD; James H. MacCabe, PhD; Michael C. O'Donovan, PhD; James T. R. Walters, PhD; and the Genetics Workstream of the Schizophrenia Treatment Resistance and Therapeutic Advances (STRATA) Consortium and the Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC)

## Supplemental content

**IMPORTANCE** About 20% to 30% of people with schizophrenia have psychotic symptoms that do not respond adequately to first-line antipsychotic treatment. This clinical presentation, chronic and highly disabling, is known as *treatment-resistant schizophrenia* (TRS). The causes of treatment resistance and their relationships with causes underlying schizophrenia are largely unknown. Adequately powered genetic studies of TRS are scarce because of the difficulty in collecting data from well-characterized TRS cohorts.

**OBJECTIVE** To examine the genetic architecture of TRS through the reassessment of genetic data from schizophrenia studies and its validation in carefully ascertained clinical samples.

**DESIGN, SETTING, AND PARTICIPANTS** Two case-control genome-wide association studies (GWAS) of schizophrenia were performed in which the case samples were defined as individuals with TRS ( $n = 10\,501$ ) and individuals with non-TRS ( $n = 20\,325$ ). The differences in effect sizes for allelic associations were then determined between both studies, the reasoning being such differences reflect treatment resistance instead of schizophrenia. Genotype data were retrieved from the CLOZUK and Psychiatric Genomics Consortium (PGC) schizophrenia studies. The output was validated using polygenic risk score (PRS) profiling of 2 independent schizophrenia cohorts with TRS and non-TRS: a prevalence sample with 817 individuals (Cardiff Cognition in Schizophrenia [CardiffCOGS]) and an incidence sample with 563 individuals (Genetics Workstream of the Schizophrenia Treatment Resistance and Therapeutic Advances [STRATA-G]).

**MAIN OUTCOMES AND MEASURES** GWAS of treatment resistance in schizophrenia. The results of the GWAS were compared with complex polygenic traits through a genetic correlation approach and were used for PRS analysis on the independent validation cohorts using the same TRS definition.

**RESULTS** The study included a total of 85 490 participants (48 635 [56.9%] male) in its GWAS stage and 1380 participants (859 [62.2%] male) in its PRS validation stage. Treatment resistance in schizophrenia emerged as a polygenic trait with detectable heritability (1% to 4%), and several traits related to intelligence and cognition were found to be genetically correlated with it (genetic correlation, 0.41-0.69). PRS analysis in the CardiffCOGS prevalence sample showed a positive association between TRS and a history of taking clozapine ( $r^2 = 2.03\%$ ;  $P = .001$ ), which was replicated in the STRATA-G incidence sample ( $r^2 = 1.09\%$ ;  $P = .04$ ).

**CONCLUSIONS AND RELEVANCE** In this GWAS, common genetic variants were differentially associated with TRS, and these associations may have been obscured through the amalgamation of large GWAS samples in previous studies of broadly defined schizophrenia. Findings of this study suggest the validity of meta-analytic approaches for studies on patient outcomes, including treatment resistance.

JAMA Psychiatry. doi:10.1001/jamapsychiatry.2021.3799  
Published online January 12, 2022.

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Group Information:** Authors and collaborators in the Genetics Workstream of the Schizophrenia Treatment Resistance and Therapeutic Advances (STRATA) Consortium and collaborators in the Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC) are listed at the end of the article.

**Corresponding Authors:** Antonio F. Pardiñas, PhD ([pardinasa@cardiff.ac.uk](mailto:pardinasa@cardiff.ac.uk)), and James T. R. Walters, PhD ([waltersjt@cardiff.ac.uk](mailto:waltersjt@cardiff.ac.uk)), MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Maindy Road, Hadyn Ellis Building, Cardiff CF24 4HQ, United Kingdom.

Precision psychiatry provides a potential pathway to improve psychiatric classification and develop treatments that are better tailored to specific patients. Major advances in determining the role of genetic variation in the risk of developing psychiatric disorders are helping realize this potential,<sup>1</sup> but the relevance of these findings to patient outcomes and response to treatment is unclear. Evidence from nonpsychiatric disorders points to distinct genetic bases for disorder susceptibility and prognosis,<sup>2,3</sup> although few sufficiently powered psychiatric genetic studies have been conducted investigating disorder progression or outcome.<sup>4</sup> Such study designs could offer valuable insights as to the feasibility of precision psychiatry approaches and their potential impact for patients who have poor outcomes because of the lack of effectiveness of current treatments.<sup>5</sup>

Some of the most disadvantaged individuals in this respect are those with a diagnosis of schizophrenia whose symptoms do not respond adequately to conventional antipsychotic medication.<sup>6-8</sup> This clinical picture is known as treatment-resistant schizophrenia (TRS), which affects approximately 20% to 30% of people with this disorder. The only licensed treatment for TRS is clozapine, which is effective in approximately 60% of cases<sup>9</sup> and improves most indicators of morbidity and mortality.<sup>10,11</sup> While the mechanism of action of clozapine is still not fully understood,<sup>12</sup> it has been proposed that its efficacy might be related to the biological underpinnings of treatment resistance, suggesting a distinct neurobiological etiology to that of non-TRS.<sup>13</sup> Additionally, several studies have shown that delay in clozapine prescription is associated with resistance even to clozapine.<sup>14,15</sup> This makes early identification of TRS critical and the ascertainment of correlates of TRS a priority for the field of schizophrenia research.

To date, there is considerable heterogeneity in the findings of genetic studies related to TRS. A family history of schizophrenia is likely associated with developing TRS,<sup>16</sup> but a recent systematic review did not find any individual genes robustly and specifically associated with this condition.<sup>17</sup> Researchers have also investigated the long-standing hypothesis that TRS is a more severe form of schizophrenia resulting from a large burden of schizophrenia risk alleles.<sup>18</sup> While 2 studies reported that aggregating risk variants into a polygenic risk score (PRS) revealed small differences between TRS and non-TRS samples,<sup>19,20</sup> other analyses did not replicate this result.<sup>16,21-23</sup> However, because each study used slightly different recruitment criteria and definitions of TRS, heterogeneity in the results is expected,<sup>24</sup> making their collective interpretation difficult. This limitation likely reflects the previously discussed problem of individuals with treatment-resistant psychiatric symptoms being disproportionately underrepresented in research studies owing to poor health, limited capacity to consent, and other causes of attrition, including therapeutic pessimism,<sup>25</sup> which have precluded the execution of well-powered genome-wide association studies (GWASs).<sup>26</sup>

In this study, we aim to characterize the contribution of common genetic variants to treatment resistance in schizophrenia by exploiting data generated by large consortium-based GWASs of schizophrenia,<sup>27,28</sup> in which individuals with

## Key Points

**Question** Can common genetic variants be used to differentiate between treatment-resistant schizophrenia (TRS) and other forms of this disorder?

**Findings** Data from this genome-wide association study including 85 490 participants were used to estimate genome-wide single-nucleotide variation effect size differences between individuals with and without TRS, which were compatible with a polygenic model of treatment resistance. Results were used to generate a polygenic risk score, which was significantly associated with TRS status in independent incidence and prevalence samples.

**Meaning** Findings of this study based on common genetic variants indicate that TRS is heritable with a modest but significant single-nucleotide variation-based heritability.

TRS can be formally defined. Our main hypotheses are that schizophrenia risk alleles will show different genetic associations in the analysis of individuals with and without TRS and that these differences reflect the underlying genetics of treatment resistance. When assessed at a genome-wide level, such differences could reveal commonalities with other complex traits or be validated in clinical cohorts using the PRS approach,<sup>29</sup> helping us to better understand the biological and epidemiological characteristics of treatment resistance in schizophrenia.<sup>17</sup>

## Methods

For our main analysis, we used samples from large genomic studies of schizophrenia.<sup>27,28</sup> Some of the largest cohorts in these research initiatives were recruited based on clozapine prescription (a proxy of TRS status), and forming a case-case data set from them would require avoiding confounding factors, such as GWAS batch effects<sup>30</sup> or population stratification,<sup>31</sup> which are difficult to control in a multiple-cohort design.<sup>32</sup> As a safeguard against these, we have used a meta-analytic procedure to assess the differences between GWAS in which individuals with TRS and non-TRS have been compared with matched sets of healthy controls, before comparing the allelic association effect sizes of these 2 GWASs on a genome-wide basis to create a GWAS specific to treatment resistance.

### Genetic Samples and Analysis

We used the CLOZUK1 and CLOZUK2 cohorts as our primary source of individuals with treatment-resistant symptoms, with a total sample size of 10 501 individuals with TRS and 24 542 controls. These cohorts have been described in previous studies.<sup>28,33</sup> All the individuals with TRS in these samples were prescribed clozapine in the UK after failure of at least 2 trials of antipsychotics, following National Institute for Health and Care Excellence guidelines for TRS.<sup>34</sup> The use of a history of taking clozapine as equivalent to a research diagnosis of TRS has been validated in these samples,<sup>28</sup> as well as in independent studies.<sup>35,36</sup> Control individuals were collected from public databases or through collaboration with population sequencing projects in the UK.

To identify individuals with non-TRS, we used 34 studies included in the meta-analysis by the Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC),<sup>27</sup> with a total sample size of 20 325 individuals with schizophrenia and 30 122 controls. In 14 of these studies, available clinical records allowed us to identify and remove all individuals with TRS (eMethods in Supplement 1). The remaining 20 studies were not screened as comparable data were not available, and thus, we conservatively included these samples in the analysis as non-treatment-resistant cases (eTable 1 in Supplement 1). Healthy control individuals in this analysis were a mixture of publicly available samples and clinically ascertained (nonpsychiatric) individuals, and extensive analyses to discard population outliers and assess stratification were also carried out.<sup>27</sup>

GWASs of individuals with TRS vs controls and individuals with non-TRS vs controls were carried out separately using the logistic regression model implemented in PLINK version 2.<sup>37</sup> Further details on the imputation, quality control, and association testing procedures are described in the eMethods in Supplement 1.

All studies used in the GWAS were reviewed and approved by their local ethical committee. Written informed consent (or legal guardian consent and participant assent) was obtained for all study participants except for those in the CLOZUK cohort, as this study used anonymized blood samples as approved by the UK Multicenter Research Ethics Committee.

## Statistical Analysis

### Comparing the TRS and Non-TRS Association Studies

To generate association statistics that reflect TRS vs non-TRS differences, we used the test for interaction proposed by Altman and Bland,<sup>38</sup> which is analogous to a fixed-effect test for moderators in the meta-analytic setting.<sup>39</sup> This test allows us to calculate an estimate of the difference between 2 odds ratios (ORs), which in our case were those of individuals with TRS vs controls (OR<sub>1</sub>) and those with non-TRS vs controls (OR<sub>2</sub>). The difference, in the scale of the regression  $\beta$  coefficient, equates to difference =  $\log(\text{OR}_1) - \log(\text{OR}_2)$ , with standard error  $\text{SE}(d) = \sqrt{(\text{SE}[\text{OR}_1]^2 + \text{SE}[\text{OR}_2]^2)}$ . We transformed this effect size into a  $z$  score and calculated its associated  $P$  value at each overlapping single-nucleotide variation (SNV; formerly single-nucleotide polymorphism) between the TRS and non-TRS GWAS, excluding 146 SNVs with a minor allele frequency difference greater than 20% between both data sets to mirror preimputation quality control. For consistency, we also used the same definition of OR<sub>1</sub> and OR<sub>2</sub> in all our tests to preserve directions of effect, and thus, positive  $z$  scores in the interaction analysis reflect stronger SNV associations in individuals with TRS compared with non-TRS.

### Estimating Heritability

SNV-based heritability was estimated from the TRS interaction summary statistics using LD Score version 1.01,<sup>40</sup> after restricting to markers present in the HapMap3 study<sup>41</sup> and a precomputed linkage disequilibrium reference panel based on the 1000 Genomes phase 3 samples. As point estimates of SNV-based heritability can differ based on model assumptions, we also estimated this quantity via the SumHer framework imple-

mented in LDAK5,<sup>42</sup> using a default parameter to define the relationship between minor allele frequency and effect size ( $\alpha = -.25$ ) and multiplicative inflation correction (genomic control). The LD reference for LDAK was estimated from the European samples of the public Haplotype Reference Consortium panel.<sup>43</sup>

### Polygenic Validation


We sought to investigate whether a TRS GWAS PRS was associated with treatment resistance status in 2 independent samples: one from a schizophrenia prevalence cohort (Cardiff Cognition in Schizophrenia [CardiffCOGS]) and the other from a first-episode incidence cohort (Genetics Workstream of the Schizophrenia Treatment Resistance and Therapeutic Advances [STRATA-G]). The CardiffCOGS prevalence cohort is a sample of individuals with schizophrenia that included both individuals with TRS and treatment-responsive schizophrenia, defined here again from a history of taking or not taking clozapine ( $n = 817$ ; 315 with TRS and 502 with non-TRS). This is a cross-sectional study with detailed clinical ratings based on research diagnostic interviews and contemporaneous records, as previously described.<sup>44</sup> We also used a new multiancestry incidence cohort of people with first-episode psychosis, the STRATA-G consortium, in which the participants have been followed up for at least 1 year after initial presentation to ascertain diagnosis and treatment response (eMethods in Supplement 1). As both the first-episode and broad psychosis nature of this sample likely make it diagnostically heterogeneous, we first restricted our analyses to individuals with a diagnosis of schizophrenia at the last time of follow-up. TRS was rated as the presence or absence of a history of taking clozapine ( $n = 562$ ; 71 with TRS and 492 with non-TRS) to best mirror our TRS GWAS and the definition used in the prevalence cohort. Further details about the recruitment and phenotyping of the STRATA-G sample as well as details of the genotyping and imputation procedure for both data sets are given in the eMethods and eTable 2 in Supplement 1.

The CardiffCOGS study had the relevant UK National Health Service ethical approval, and studies included in STRATA-G were reviewed and approved by their local ethical committees. Written informed consent was obtained for all participants.

### PRS Analysis

Our primary PRS analysis used the TRS interaction GWAS summary statistics as training set, and the prevalence and incidence cohorts as testing sets where their treatment-resistance phenotype was tested for association. We also investigated the association of PRS and treatment resistance status based on (1) the CLOZUK TRS vs healthy control GWAS and (2) the PGC non-TRS GWAS. Polygenic scores were estimated using PRSice-2 version 2.35<sup>45</sup> and PRS-CS version June 4, 2021,<sup>46</sup> as detailed in the eMethods in Supplement 1. Within each pairing of training and testing set, PRS association  $P$  values were corrected for multiple testing using the Benjamini and Hochberg false discovery rate (FDR) method<sup>47</sup> as implemented in the R framework *stats* package.

Figure 1. Manhattan Plot of the Treatment-Resistant Schizophrenia (TRS) vs Non-TRS Interaction Genome-Wide Association Study



### Estimating Genetic Correlation and Colocalization

Correlations between treatment resistance and other complex traits were computed using LD-Hub version 1.93,<sup>48</sup> again based on the LD-Score regression<sup>40</sup> framework. We only performed the analysis for GWAS categories that had significant phenome-wide associations with psychiatric disorders, based on previous research.<sup>49</sup> The categories chosen were education, cognitive, personality, psychiatric, and smoking, for a total of 28 summary statistics. Multiple testing correction of these results was also carried out using FDR, since most of the summary statistics tested have overlapping samples and thus yield partially dependent *P* values.

For all associations, statistical significance was set at  $P < .05$ . All *P* values were 2-tailed.

## Results

### TRS/Non-TRS GWAS

The study included a total of 85 490 participants (48 635 [56.9%] male) in its GWAS stage and 1380 participants (859 [62.2%] male) in its PRS validation stage. Discovery GWAS of individuals with TRS and non-TRS against independent controls showed highly consistent genome-wide significant signals (eFigure 1 in Supplement 1), all reported in previous schizophrenia studies. This consistency extended to most of the polygenic architecture, as shown by a high genetic correlation estimate between the data sets ( $r = 0.966$ ; SE, 0.037;  $P = 1.43 \times 10^{-147}$ ) in which the 95% CI includes 1. No genome-wide SNVs were detected by the TRS interaction analysis (Figure 1), although a slight departure from normality was detected in the genome-wide Q-Q plot ( $\lambda = 1.062$ ;  $\lambda_{1000} = 1.002$ ; LD-Score intercept, 1.032; SE, 0.007; LDAK scaling estimate, 1.017; SE, 0.010; eFigure 2 in Supplement 1). This is compatible with a polygenic signal,<sup>50</sup> as the 2 discovery GWASs did not show evidence of inflation caused by other confounding factors.<sup>27,28</sup> Indeed, the 2 methods we used to estimate


the common variant contribution to the observed-scale heritability of TRS returned small values of similar magnitude (SNV-based heritability: LD-Score, 0.013; SE, 0.006; SNV-based heritability: LDAK, 0.040; SE, 0.014).

### Polygenic Score–Based Prediction of TRS in Independent Samples

A PRS generated from the TRS interaction GWAS was positively associated with treatment resistance in our validation prevalence cohort (CardiffCOGS), explaining up to 2.03% of the variance on the liability scale of treatment resistance ( $P = .001$ ; FDR  $P = .01$ ; Figure 2; eTable 3 in Supplement 1). Analyzing the 2 GWASs used in the interaction analysis, we found that a PRS based on CLOZUK GWAS results (TRS vs healthy controls) also explained a significant proportion of the variance in the TRS phenotype (maximum  $r^2 = 1.63\%$ ;  $P = .004$ ; FDR  $P = .03$ ), very similar to that obtained by testing the larger PGC non-TRS sample (maximum  $r^2 = 1.21\%$ ;  $P = .01$ ; FDR  $P = .10$ ). However, the effect sizes of these PRSs were generally in opposite directions (Figure 2; eTable 3 in Supplement 1); ie, those taking clozapine in CardiffCOGS had higher PRS derived from the TRS GWAS (OR, 1.22; 95% CI, 1.05-1.41) but a lower PRS from the non-TRS GWAS (OR, 0.83; 95% CI, 0.72-0.96). Focusing on the polygenic prediction via Bayesian regression and continuous shrinkage priors estimates, which do not require LD clumping or *P* value thresholding,<sup>51</sup> we also observed a significant and positive difference between the effect sizes of the TRS interaction and CLOZUK PRS, while the PGC PRS had a null effect (Figure 2). This pattern of results in an independent case-case comparison is consistent with our interaction analysis detecting a true polygenic signal for treatment resistance, with a greater burden of risk alleles from both this and the CLOZUK TRS GWAS associating with a history of clozapine prescription. Alternatively, the PRS derived from non-TRS samples is not as clearly associated with treatment resistance, and some results of these analyses are even compatible with its enrichment in individuals with non-TRS.



**Figure 2. Polygenic Score Analysis of the Cardiff Cognition in Schizophrenia (CardiffCOGS) Cohort and Genetics Workstream of the Schizophrenia Treatment Resistance and Therapeutic Advances (STRATA-G) Cohort Using 3 Different Schizophrenia-Related Polygenic Risk Scores (PRS)**



Associations between PRS and treatment resistance in schizophrenia (TRS) were defined as a history of taking clozapine in people with a schizophrenia diagnosis. There were 315 individuals with TRS and 502 individuals with non-TRS in the CardiffCOGS cohort and 71 individuals with TRS and 492 control individuals in the STRATA-G cohort. PGC indicates Psychiatric Genomics

Consortium; PRS-CS, polygenic prediction via Bayesian regression and continuous shrinkage priors. Whiskers indicate 95% CIs.

<sup>a</sup>  $P < .05$ .

Generation of PRS and their analysis within the first-episode incidence sample (STRATA-G) showed that a greater interaction PRS burden was also associated with having treatment resistance in this setting, explaining up to 1.09% of the variance ( $P = .04$ ; FDR  $P = .21$ ). In contrast, neither the CLOZUK nor PGC PRS were significantly associated with treatment resistance across any of the tested  $P$  value thresholds or using polygenic prediction via Bayesian regression and continuous shrinkage priors (Figure 2; eTable 3 in Supplement 1). However, a meta-analysis of both CardiffCOGS and STRATA-G resulted in narrower confidence intervals around all the PRS effect size estimates previously estimated from CardiffCOGS, supporting the overall consistency in directions of association between these samples (eFigure 3 and eTable 3 in Supplement 1).


To interpret the results from the prevalence and incidence cohorts alongside each other, we merged the genotyped SNVs from both samples (to a total of 199 074 SNVs) and estimated polygenic scores using all LD-independent SNVs ( $P < 1$ ). As a reference point for this analysis, we retained a small subset of 242 screened unaffected control individuals that had been genotyped as part of the Genetics and Psychosis project,<sup>26</sup>

one of the STRATA-G cohorts. Splitting the combined sample by TRS status showed that the polygenic profile of treatment resistance is largely consistent between CardiffCOGS and STRATA-G, with the TRS interaction PRS burden showing no difference between incident and prevalent TRS individuals (Figure 3). However, we noted a distinction in terms of general schizophrenia risk alleles, as indexed by the CLOZUK and PGC PRS, which were enriched within the individuals with first-episode TRS compared with the individuals with TRS from our cross-sectional sample (CLOZUK: OR, 1.52; SE, 0.21;  $P = .047$ ; PGC: OR, 3.48; SE, 0.39;  $P = 7.69 \times 10^{-4}$ ). None of the scores we tested were significantly different between the 2 groups of individuals with non-TRS, and all individuals with schizophrenia showed larger mean scores than the unaffected controls.

#### Genetic Correlation Between TRS and Other Traits

We used the results of the TRS interaction GWAS to examine the genetic associations between the treatment-resistant phenotype and other disorders and traits. In these analyses, 8 of 28 publicly available GWAS summary statistics displayed nominally significant ( $P < .05$ ) genetic correlations with TRS, of which 5 survived multiple testing correction (FDR  $p < 0.05$ ;


**Figure 3. Polygenic Profile Derived From Combined Genotype Data From the Cardiff Cognition in Schizophrenia (CardiffCOGS) and Genetics Workstream of the Schizophrenia Treatment Resistance and Therapeutic Advances (STRATA-G) Cohorts Using Scores Calculated With Linkage Disequilibrium-Independent ( $P < 1$ ) Single-Nucleotide Variants**



Dots indicate the mean values of the standardized polygenic risk score (PRS; corrected for sex, relevant principal components, and ancestry-informative marker-based ancestry estimates). Whiskers delimit the 95% CIs of the PRS

means. PGC indicates Psychiatric Genomics Consortium; TRS, treatment-resistant schizophrenia.

**Figure 4. Linkage Disequilibrium Score Regression Genetic Correlation Results of LD-HUB Phenotypes With the Treatment-Resistant Schizophrenia Interaction Genome-Wide Association Study**



Top, Genetic correlation coefficients shown with standard errors. Bottom, Genetic correlation  $P$  values. The dashed line indicates a false discovery rate-corrected significant level of  $P = .05$ .

**Figure 4;** eTable 4 in Supplement 1). All 5 genetically correlated phenotypes were associated with cognitive measures and educational attainment (genetic  $r$ , 0.41-0.69), showing our GWAS of TRS to be genetically correlated with lower cognitive ability and lower educational attainment.

## Discussion

We report a large study of treatment resistance in schizophrenia, showing that common genetic variants were associated

with this presentation, that these variants were also associated with general risk of schizophrenia, and that the difference in their associations with the 2 phenotypes may have influenced the polygenic score analyses. Furthermore, our results, particularly the large genetic correlation between the TRS and non-TRS GWASs, are consistent with the risk conferred by common SNVs being similar regardless of whether individuals respond to first-line treatments. This suggests that treatment resistance, at least to the extent that we have been able to define it and explore it within this study, is not likely to index a cluster of individuals with a range of etiologies and pathophysiologies fundamentally different from those that contribute to schizophrenia more widely. However, by also assessing differences at the level of individual allelic associations, our results also support the existence of a polygenic contribution associated with treatment resistance that seems largely distinct from liability to schizophrenia. While this approach has not identified specific SNVs or genes that could be followed up as potential drivers of treatment outcomes, we find genome-wide correlations that recapitulate previous epidemiological findings, such as the association of treatment resistance with poorer cognitive performance.<sup>52,53</sup> Such polygenic overlaps validate our indirect approach for carrying out the GWAS of TRS in the absence of a single large-scale harmonized case-case sample. However, they should not be interpreted as proof of causality in either direction and do not account for confounders, such as sociodemographic indicators, medication adherence, or antipsychotic effects in treatment response.

## Implications

In revealing the existence of a common, heritable genetic signal for TRS, our study adds a new layer of evidence to the ongoing discussion of whether TRS is categorically distinct from treatment-responsive schizophrenia.<sup>17</sup> Despite a large genetic correlation between both conditions, we show that PRS derived from them perform differently when attempting out-of-sample prediction of TRS, which suggests that the heterogeneous results previously obtained in PRS analyses might have been influenced by the presence of individuals with TRS in the generic schizophrenia training sample.<sup>19</sup> While

follow-up studies would likely require rich clinical data on large numbers of individuals with TRS and non-TRS to fully explore the implications of these results, they pose an important consideration for research seeking to understand whether the genetics of disorder susceptibility are the same as disease course in schizophrenia<sup>2</sup> and whether treatment response can be influenced by the accumulation of genetic and clinical factors.<sup>54,55</sup> Finally, while our results show that TRS is associated with a polygenic signal, the variance in TRS explained remains modest, and associated area under the curve values are small (eTable 3 in Supplement 1). Thus, polygenic scores tapping into this signal are thus unlikely to be of clinical utility in predicting treatment resistance, although their contribution to multifactorial predictive models (integrating rare variants, neuroimaging biomarkers, environmental exposures, demographic factors, and clinical measures) is an interesting avenue for future research.

### Limitations

This study has limitations. TRS is an underreported diagnosis, and while our research definition for this phenotype aligns with international criteria,<sup>56</sup> we acknowledge that some individuals with treatment-resistant symptoms might still be present in the non-TRS data set, particularly in those samples where no ascertainment of TRS could be carried out. The effect of such misclassification would be akin to a reduction of effective sample size, reducing SNV discovery power and adding noise to GWAS effect size estimates.<sup>57</sup> This further limits our power to detect differences in allelic associations through the interaction analysis, which is already only sensitive to relatively large differences in effect size between studies.<sup>58</sup> Additionally, the interaction test does not model or addresses potential between-study heterogeneity. This precludes the use

of more sophisticated statistical methods for downstream analyses, such as tissue-specific enrichment analyses or transcriptome-wide association studies.<sup>59</sup>

Imperfect phenotyping and potential misclassification might also have attenuated our results, and given the small total heritability detected for our TRS GWAS, we note that the magnitude of genetic correlations with other traits should be interpreted cautiously. Also, similar to what has been argued in the study of etiologically heterogeneous phenotypes through GWAS,<sup>50,60</sup> the existence of significant genetic correlations and consistent polygenic association in independent samples reassures us that the common genetic variants we detect have (en masse) an association with TRS liability, even if our results cannot quantify the degree of contribution from nongenetic causes. In this regard, given that most of our analyses are based on European-based and UK-based samples, our conclusions might not be generalizable to non-European countries, where the diagnosis and treatment pathways of TRS might be influenced by racial and ethnic or cultural backgrounds.<sup>61</sup>

### Conclusions

In this GWAS, TRS had a small but detectable heritability associated with common risk alleles. Validation work, via the PRS method, showed that the contribution of these alleles were similar across incidence and prevalence samples. This is despite differences in cohort characteristics, and the use of drug prescription data as a proxy for TRS instead of quantitative metrics. Altogether, these results highlight the usefulness of well-controlled clinical phenotype data in psychiatric genetics to explore beyond diagnostic classifications and into treatment outcome and response to aid precision psychiatry.

#### ARTICLE INFORMATION

**Accepted for Publication:** November 2, 2021.

**Published Online:** January 12, 2022.

doi:10.1001/jamapsychiatry.2021.3799

**Open Access:** This is an open access article distributed under the terms of the [CC-BY License](https://creativecommons.org/licenses/by/4.0/).

© 2022 Pardiñas AF et al. *JAMA Psychiatry*.

**Author Affiliations:** MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, United Kingdom (Pardiñas, Smart, Willcocks, Holmans, Dennison, Lynham, Legge, Owen, O'Donovan, Walters); Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom (Smart, Murray, MacCabe); Department of Psychiatry, University of Münster, Münster, Germany (Baune); Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Australia (Baune); The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Australia (Baune); Department of Psychiatry and the Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn (Bigdeli, Fanous); Institute for Genomic Health, State University of New York Downstate

Medical Center, Brooklyn (Bigdeli, Fanous); Department of Psychiatry, Veterans Affairs New York Harbor Healthcare System, Brooklyn (Bigdeli); School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, Australia (Cairns, Tooney); Centre for Brain and Mental Health Research, University of Newcastle, Newcastle, Australia (Cairns); Hunter Medical Research Institute, Newcastle, Australia (Cairns, Tooney); Neuropsychiatric Genetics Research Group, Department of Psychiatry, Trinity College Dublin, Dublin, Ireland (Corvin); Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Mannheim, Germany (Frank, Rietschel); School of Medicine & Public Health, The University of Newcastle, Newcastle, Australia (Kelly); Molecular Psychiatry Laboratory, Division of Psychiatry, University College London, London, United Kingdom (McQuillin); Norwegian Centre for Mental Disorders Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (Melle, Simonsen, Andreassen); Division of Mental Health and Addiction, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway (Melle, Andreassen); National Centre for Register-based Research, Aarhus University, Aarhus, Denmark (Mortensen); The Lundbeck Foundation Initiative

for Integrative Psychiatric Research, Aarhus, Denmark (Mortensen); Queensland Brain Institute, The University of Queensland, Brisbane, Australia (Mowry, Periyasamy); Queensland Centre for Mental Health Research, The University of Queensland, Brisbane, Australia (Mowry, Periyasamy); Department of Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, Brooklyn (Pato); Department of Psychiatry and Zilkha Neurogenetics Institute, Keck School of Medicine, University of Southern California, Los Angeles (Pato); Institute for Genomic Health, State University of New York Downstate Medical Center, Brooklyn (Pato); University Clinic and Outpatient Clinic for Psychiatry, Psychotherapy and Psychosomatics, Martin Luther University of Halle-Wittenberg, Halle, Germany (Rujescu); Division of General Psychiatry, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria (Rujescu); Early Intervention in Psychosis Advisory Unit for South-East Norway, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (Simonsen); Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom (St Clair); Baker Heart and Diabetes Institute, Melbourne, Australia (Wu); College of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada (Kowalec);

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Kowalec, Sullivan); Department of Psychiatry, Icahn School of Medicine, Mount Sinai Hospital, New York, New York (Sullivan); Department of Genetics, University of North Carolina, Chapel Hill (Sullivan).

**Authors of the Genetics Workstream of the Schizophrenia Treatment Resistance and Therapeutic Advances (STRATA) Consortium:**

Olesya Ajnakina, PhD; Luis Alameda, MD; Thomas R. E. Barnes, DSc; Domenico Berardi, MD; Elena Bonora, PhD; Sara Camporesi, MD; Martine Cleusix, PhD; Philippe Conus, MD; Benedicto Crespo-Facorro, MD, PhD; Giuseppe D'Andrea, MD; Arsime Demjaha, MBBS, PhD; Kim Q. Do, PhD; Gillian A. Doody, MD; Chin B. Eap, PhD; Aziz Ferchiou, MD; Marta Di Forti, MD, PhD; Lorenzo Guidi, MSc; Lina Homman, PhD; Raoul Jenni, PhD; Eileen M. Joyce, MD, PhD; Laura Kassoumeri, BSc; Inês Khadimallah, PhD; Ornella Lastrina, PhD; Roberto Muratori, MD, PhD; Handan Noyan, PhD; Francis A. O'Neill, PhD; Baptiste Pignon, MD; Romeo Restellini, MD; Jean-Romain Richard, MSc; Frank Schürhoff, MD; Filip Španiel, MD, PhD; Andrei Szöke, MD, PhD; Iliaria Tarricone, MD, PhD; Andrea Tortelli, MD, PhD; Alp Üçok, MD; Javier Vázquez-Bourgon, MD, PhD.

**Affiliations of Authors of the Genetics Workstream of the Schizophrenia Treatment Resistance and Therapeutic Advances (STRATA) Consortium:**

Department of Biostatistics & Health Informatics, Institute of Psychiatry, Psychology & Neuroscience, King's College London, University of London, London, United Kingdom (Ajnakina); Department of Behavioural Science and Health, Institute of Epidemiology and Health Care, University College London, London, United Kingdom (Ajnakina); Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom (Alameda, Demjaha, Kassoumeri); Centro de Investigación Biomedica en Red de Salud Mental, Spanish Network for Research in Mental Health, Sevilla, Spain (Alameda, Crespo-Facorro); Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Departamento de Psiquiatria, Universidad de Sevilla, Sevilla, Spain (Alameda, Crespo-Facorro); Treatment and Early Intervention in Psychosis Program, Service of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland (Alameda, Camporesi, Conus, Restellini); Division of Psychiatry, Imperial College London, London, United Kingdom (Barnes); Department of Biomedical and Neuro-motor Sciences, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Bologna, Italy (Berardi, D'Andrea, Lastrina); Department of Medical and Surgical Sciences, Bologna Transcultural Psychosomatic Team, Alma Mater Studiorum, University of Bologna, Bologna, Italy (Bonora, Guidi, Muratori, Tarricone); Unit for Research in Schizophrenia, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland (Camporesi, Cleusix, Do, Jenni, Khadimallah, Restellini); Department of Medical Education, University of Nottingham Faculty of Medicine and Health Sciences, Nottingham, United Kingdom (Doody); Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne

University Hospital, University of Lausanne, Prilly, Switzerland (Eap); School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland (Eap); Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland (Eap); Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland (Eap); University Paris-Est Créteil, Institut national de la santé et de la recherche médicale, Mondor Institute for Biomedical Research, Translational Neuropsychiatry, Fondation FondaMental, Créteil, France (Ferchiou, Pignon, Richard, Schürhoff, Szöke, Tortelli); Social Genetics and Developmental Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom (Di Forti); South London and Maudsley National Health Service Mental Health Foundation Trust, London, United Kingdom (Di Forti); Department of Social and Welfare Studies, Department of Behavioural Sciences and Learning, Linköping University, Linköping, Sweden (Homman); Centre For Public Health, Institute Of Clinical Sciences, Queens University Belfast, Belfast, United Kingdom (Homman, O'Neill); UCL Queen Square Institute of Neurology, University College London, London, United Kingdom (Joyce); Faculty of Social Sciences, Department of Psychology, Beykoz University, Istanbul, Turkey (Noyan); Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Hôpital, Département Médico-Universitaire de Psychiatrie et d'Addictologie, Fédération Hospitalo-Universitaire de Médecine de Précision, Créteil, France (Pignon, Schürhoff, Szöke); Department of Applied Neuroscience and Neuroimaging, National Institute of Mental Health, Klecany, Czechia (Španiel); Department of Psychiatry and Medical Psychology, Third Faculty of Medicine, Charles University, Prague, Czechia (Španiel); Groupe Hospitalier Universitaire Psychiatrie Neurosciences Paris, Pôle Psychiatrie Précarité, Paris, France (Tortelli); Department of Psychiatry, Istanbul University, Istanbul, Turkey (Üçok); Department of Psychiatry, University Hospital Marques de Valdecilla-Instituto de Investigación Marques de Valdecilla, Santander, Spain (Vázquez-Bourgon); Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, Santander, Spain (Vázquez-Bourgon); Centro de Investigación Biomedica en Red de Salud Mental, Spanish Network for Research in Mental Health, Santander, Spain (Vázquez-Bourgon).

**Author Contributions:** Dr Pardiñas had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Pardiñas, Conus, Corvin, Kelly, McQuillin, O'Neill, Periyasamy, St Clair, Murray, MacCabe, O'Donovan, Walters.

**Acquisition, analysis, or interpretation of data:** Pardiñas, Smart, Willcocks, Holmans, Dennison, Lynham, Legge, Kassoumeri, Ajnakina, Alameda, Barnes, Baune, Berardi, Bigdeli, Bonora, Cairns, Camporesi, Cleusix, Conus, Corvin, Crespo-Facorro, D'Andrea, Demjaha, Do, Doody, Eap, Fanous, Ferchiou, Di Forti, Frank, Guidi, Homman, Jenni, Joyce, Khadimallah, Lastrina, McQuillin, Melle, Mortensen, Mowry, Muratori, Noyan, Pato, Pignon, Restellini, Richard, Rietschel, Rujescu, Schurhoff, Simonsen, Spaniel, St Clair, Szöke, Tarricone, Tooney, Tortelli, Uçok, Vázquez-Bourgon, Wu,

Andreassen, Kowalec, Sullivan, Murray, Owen, MacCabe, O'Donovan, Walters.

**Drafting of the manuscript:** Pardiñas, Kassoumeri, Joyce, Khadimallah, Lastrina, O'Neill, Schurhoff, O'Donovan, Walters.

**Critical revision of the manuscript for important intellectual content:** Pardiñas, Smart, Willcocks, Holmans, Dennison, Lynham, Legge, Ajnakina, Alameda, Barnes, Baune, Berardi, Bigdeli, Bonora, Cairns, Camporesi, Cleusix, Conus, Corvin, Crespo-Facorro, D'Andrea, Demjaha, Do, Doody, Eap, Fanous, Ferchiou, Di Forti, Frank, Guidi, Homman, Jenni, Kelly, McQuillin, Melle, Mortensen, Mowry, Muratori, Noyan, Pato, Pignon, Periyasamy, Restellini, Richard, Rietschel, Rujescu, Simonsen, Spaniel, St Clair, Szöke, Tarricone, Tooney, Tortelli, Uçok, Vázquez-Bourgon, Wu, Andreassen, Kowalec, Sullivan, Murray, Owen, MacCabe, O'Donovan, Walters.

**Statistical analysis:** Pardiñas, Smart, Willcocks, Holmans, Lynham, Bigdeli, Frank.

**Obtained funding:** Conus, Corvin, Do, Di Forti, Melle, Mortensen, Mowry, O'Neill, Pato, Rietschel, Spaniel, St Clair, Sullivan, Murray, Owen, MacCabe, O'Donovan, Walters.

**Administrative, technical, or material support:**

Pardiñas, Dennison, Legge, Kassoumeri, Ajnakina, Alameda, Berardi, Bonora, Cairns, Doody, Eap, Fanous, Homman, Joyce, Khadimallah, McQuillin, Melle, Noyan, Pato, Periyasamy, Restellini, Richard, Rietschel, Simonsen, Spaniel, Uçok, Wu, Andreassen, Kowalec, Murray, Walters.

**Supervision:** Conus, Crespo-Facorro, Do, Doody, McQuillin, Pignon, Rujescu, Murray, Owen, MacCabe, O'Donovan, Walters.

**Conflict of Interest Disclosures:** Dr Baune has received grants from EraPerMED as well as personal fees from AstraZeneca, Lundbeck, Pfizer, Takeda Pharmaceuticals, Servier, Bristol Myers Squibb, Otsuka, LivaNova, and Janssen-Cilag. Dr Andreassen has received grants from KG Jebsen Stiftelsen, South East Norway Health Authority, Research Council of Norway, and the European Union Horizon 2020 as well as personal fees from HealthLytix, Lundbeck, and Sunovion. Dr Sullivan has received research funding from Lundbeck as well as personal fees from Pfizer, Neumora, Element Genomics, and Roche; is a shareholder of Neumora; and serves on the advisory committee of Lundbeck. Dr Murray has received grants from Medical Research Council as well as personal fees from Janssen, Merck, Otsuka, Sunovian, and Lundbeck. Drs Owen, O'Donovan, and Walters are investigators on a grant from Takeda Pharmaceuticals paid to Cardiff University; Dr Smart is employed by funds from this grant. Dr MacCabe has received research funding and nonfinancial support from Lundbeck. Dr O'Donovan reported grants from the National Institutes of Health, UK Medical Research Council, Commission of the European Union, and Takeda Pharmaceuticals. Dr Walters has received grants from Medical Research Council, National Institutes of Health, and European Union 7th Framework Programme for Research, and Takeda Pharmaceuticals. Dr Barnes is a member of an advisory board for Gedeon Richter. Dr Camporesi has received grants from the Swiss National Centre Competence in Research. Dr Crespo-Facorro has received personal fees from Adamed, Mylan, Angelini, Janssen, Johnson & Johnson, Lundbeck, and Otsuka Pharmaceuticals. Dr Do has received grants from the Swiss National Science Foundation,



and Boehringer Ingelheim and has a patent for EP19218841.5 pending. Dr Epap has received grants from the Swiss National Science Foundation and personal fees from Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Vifor Pharma, and Zeller. Dr Di Forti has received fees for educational seminars from Lundbeck and Janssen. Dr Szöke has received grants from the European Community's Seventh Framework Programme. No other disclosures were reported.

**Funding/Support:** This work was supported by Medical Research Council Centre grant MR/L010305/1, Medical Research Council Program grant MR/PO05748/1, and Medical Research Council Project grants MR/L011794/1 and MC\_PC\_17212 to Cardiff University and by the National Centre for Mental Health, funded by the Welsh Government through Health and Care Research Wales. This work acknowledges the support of the Supercomputing Wales project, which is partially funded by the European Regional Development Fund via the Welsh Government. Dr Pardiñas was supported by an Academy of Medical Sciences Springboard Award (SBFO051083). Dr Andreassen was supported by the Research Council of Norway (grants 283798, 262656, 248980, 273291, 248828, 248778, and 223273); KG Jepsen Stiftelsen, South-East Norway Health Authority, and the European Union's Horizon 2020 Research and Innovation Programme (grant 847776). Dr Ajakina was supported by an National Institute for Health Research postdoctoral fellowship (PDF-2018-11-ST2-020). Dr Joyce was supported by the University College London Hospitals/UCL University College London Biomedical Research Centre. Dr Kowalec received funding from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement (793530) from the government of Canada Banting postdoctoral fellowship programme and the University of Manitoba. Dr Sullivan was supported by the Swedish Research Council (Vetenskapsrådet, DO886501), the European Union's Horizon 2020 programme (COSYN, 610307) and the US National Institute of Mental Health (U01 MH109528 and R01 MH077139). The Psychiatric Genomics Consortium was partly supported by the National Institute of Mental Health (grants R01MH124873). The Sweden Schizophrenia Study was supported by the National Institute of Mental Health (grant R01MH077139). The STRATA consortium was supported by a Stratified Medicine Programme grant to Dr MacCabe from the Medical Research Council (grant MR/L011794/1), which funded the research and supported Drs Pardiñas, Smart, Kassoumeri, Murray, Walters, and MacCabe. Dr Smart was supported by a Collaboration for Leadership in Applied Health Research and Care South London at King's College Hospital National Health Service Foundation Trust. The AESOP (US) cohort was funded by the UK Medical Research Council (grant G0500817). The Belfast (UK) cohort was funded by the Research and Development Office of Northern Ireland. The Bologna (Italy) cohort was funded by the European Community's Seventh Framework program (HEALTH-F2-2010-241909, project EU-GEI). The Genetics and Psychosis project (London, UK) cohort was funded by the UK National Institute of Health Research Specialist Biomedical Research Centre for Mental Health, South London and the Maudsley National Health Service Mental Health Foundation Trust (SLAM) and

the Institute of Psychiatry, Psychology, and Neuroscience at King's College London; Psychiatry Research Trust; Maudsley Charity Research Fund; and the European Community's Seventh Framework program (HEALTH-F2-2009-241909, project EU-GEI). The Lausanne (Switzerland) cohort was funded by the Swiss National Science Foundation (grants 320030\_135736/1, 320030-120686, 324730-144064, 320030-173211, and 171804); the National Center of Competence in Research Synaptic Bases of Mental Diseases from the Swiss National Science Foundation (grant 51AU40\_125759); and Fondation Alamaya. The Oslo (Norway) cohort was funded by the Research Council of Norway (grant 223273/F50, under the Centers of Excellence funding scheme, 300309, 283798) and the South-Eastern Norway Regional Health Authority (grants 2006233, 2006258, 2011085, 2014102, 2015088, and 2017-112). The Paris (France) cohort was funded by European Community's Seventh Framework program (HEALTH-F2-2010-241909, project EU-GEI). The Prague (Czech Republic) cohort was funded by the Ministry of Health of the Czech Republic (grant NU20-04-00393). The Santander (Spain) cohort was funded by the following grants to Dr Crespo-Facorro: Instituto de Salud Carlos III (grants FIS00/3095, PI020499, PI050427, and PI060507), Plan Nacional de Drogas Research (grant 2005-Orden sco/3246/2004), SENY Fundatio Research (grant 2005-0308007), Fundacion Marques de Valdecilla (grant A/02/07, API07/011) and Ministry of Economy and Competitiveness and the European Fund for Regional Development (grants SAF2016-76046-R and SAF2013-46292-R). The West London (UK) cohort was funded by The Wellcome Trust (grants 042025, 052247, and 064607).

**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Group Information:** The Genetics Workstream of the Schizophrenia Treatment Resistance and Therapeutic Advances (STRATA) Consortium and the Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC) collaborators appear in Supplement 2.

**Disclaimer:** The research content reported in this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The views expressed are those of the authors and not necessarily those of the Medical Research Council, National Health Service, the National Institute for Health Research, or the Department of Health.

**Additional Information:** Summary statistics from the treatment-resistant schizophrenia interaction genome-wide association study can be downloaded from <https://walters.psychm.cf.ac.uk/>.

## REFERENCES

- Sullivan PF, Agrawal A, Bulik CM, et al; Psychiatric Genomics Consortium. Psychiatric genomics: an update and an agenda. *Am J Psychiatry*. 2018;175(1):15-27. doi:10.1176/appi.ajp.2017.17030283
- Paternalster L, Tilling K, Davey Smith G. Genetic epidemiology and mendelian randomization for informing disease therapeutics: conceptual and

methodological challenges. *PLoS Genet*. 2017;13(10):e1006944. doi:10.1371/journal.pgen.1006944

- Lee JC, Biacci D, Roberts R, et al; UK IBD Genetics Consortium. Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease. *Nat Genet*. 2017;49(2):262-268. doi:10.1038/ng.3755
- Rees E, Owen MJ. Translating insights from neuropsychiatric genetics and genomics for precision psychiatry. *Genome Med*. 2020;12(1):43. doi:10.1186/s13073-020-00734-5
- Birnbaum R, Weinberger DR. Special article: translational science update. pharmacological implications of emerging schizophrenia genetics: can the bridge from 'genomics' to 'therapeutics' be defined and traversed? *J Clin Psychopharmacol*. 2020;40(4):323-329. doi:10.1097/JCP.0000000000001215
- Lally J, Gaughran F, Timms P, Curran SR. Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics. *Pharmacogenomics Pers Med*. 2016;9:117-129. doi:10.2147/PGPM.S115741
- Mørup MF, Kymes SM, Oudin Åström D. A modelling approach to estimate the prevalence of treatment-resistant schizophrenia in the United States. *PLoS One*. 2020;15(6):e0234121. doi:10.1371/journal.pone.0234121
- Siskind D, Orr S, Sinha S, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. *Br J Psychiatry*. 2021;1-6. doi:10.1192/bjp.2021.61
- Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. *Biol Psychiatry*. 2008;63(5):524-529. doi:10.1016/j.biopsych.2007.04.043
- Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. *Biol Psychiatry*. 2001;50(11):898-911. doi:10.1016/S0006-3223(01)01271-9
- Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. *JAMA Psychiatry*. 2017;74(7):686-693. doi:10.1001/jamapsychiatry.2017.1322
- Pardiñas AF, Owen MJ, Walters JTR. Pharmacogenomics: a road ahead for precision medicine in psychiatry. *Neuron*. 2021;S0896-6273(21)00683-8.
- Krivoy A, Hochman E, Sendt K-V, et al. Association between serum levels of glutamate and neurotrophic factors and response to clozapine treatment. *Schizophr Res*. 2018;192:226-231. doi:10.1016/j.schres.2017.05.040
- Shah P, Iwata Y, Brown EE, et al. Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. *Eur Arch Psychiatry Clin Neurosci*. 2020;270(1):11-22. doi:10.1007/s00406-019-01053-6
- Shah P, Iwata Y, Plitman E, et al. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review. *Psychiatry Res*. 2018;268:114-122. doi:10.1016/j.psychres.2018.06.070
- Kowalec K, Lu Y, Sariasslan A, et al. Increased schizophrenia family history burden and reduced premorbid IQ in treatment-resistant schizophrenia: a Swedish National Register and Genomic Study. *Mol Psychiatry*. 2021;26(8):4487-4495. doi:10.1038/s41380-019-0575-1
- Gillespie AL, Samanaitte R, Mill J, Egerton A, MacCabe JH. Is treatment-resistant schizophrenia

- categorically distinct from treatment-responsive schizophrenia? a systematic review. *BMC Psychiatry*. 2017;17(1):12. doi:10.1186/s12888-016-1177-y
18. Sobell JL, Mikesell MJ, McMurray CT. Genetics and etiopathophysiology of schizophrenia. *Mayo Clin Proc*. 2002;77(10):1068-1082. doi:10.4065/77.10.1068
19. Frank J, Lang M, Witt SH, et al. Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. *Mol Psychiatry*. 2015; 20(2):150-151. doi:10.1038/mp.2014.56
20. Gasse C, Wimberley T, Wang Y, et al. Schizophrenia polygenic risk scores, urbanicity and treatment-resistant schizophrenia. *Schizophr Res*. 2019;212:79-85. doi:10.1016/j.schres.2019.08.008
21. Martin AK, Mowry B. Increased rare duplication burden genome-wide in patients with treatment-resistant schizophrenia. *Psychol Med*. 2016;46(3):469-476. doi:10.1017/S0033291715001701
22. Legge SE, Dennison CA, Pardiñas AF, et al. Clinical indicators of treatment-resistant psychosis. *Br J Psychiatry*. 2020;216(5):259-266. doi:10.1192/bjp.2019.120
23. Wimberley T, Gasse C, Meier SM, Agerbo E, MacCabe JH, Horsdal HT. Polygenic risk score for schizophrenia and treatment-resistant schizophrenia. *Schizophr Bull*. 2017;43(5):1064-1069. doi:10.1093/schbul/sbx007
24. Hodgson K, McGuffin P, Lewis CM. Advancing psychiatric genetics through dissecting heterogeneity. *Hum Mol Genet*. 2017;26(R2):R160-R165. doi:10.1093/hmg/ddx241
25. Hofer A, Radner V, Edlinger M, Kemmler G, Rettenbacher MA, Fleischhacker WW. Why do individuals with schizophrenia drop out of observational clinical trials? *Psychiatry Res*. 2017; 256:1-5. doi:10.1016/j.psychres.2017.06.010
26. Lally J, Ajnakina O, Di Forti M, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. *Psychol Med*. 2016;46(15):3231-3240. doi:10.1017/S0033291716002014
27. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 2014;511(7510):421-427. doi:10.1038/nature13595
28. Pardiñas AF, Holmans P, Pocklington AJ, et al; GERAD1 Consortium; CRESTAR Consortium. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nat Genet*. 2018;50(3):381-389. doi:10.1038/s41588-018-0059-2
29. Wray NR, Lee SH, Mehta D, Vinkhuyzen AAE, Dudbridge F, Middeldorp CM. Research review: polygenic methods and their application to psychiatric traits. *J Child Psychol Psychiatry*. 2014; 55(10):1068-1087. doi:10.1111/jcpp.12295
30. Sinnott JA, Kraft P. Artifact due to differential error when cases and controls are imputed from different platforms. *Hum Genet*. 2012;131(1):111-119. doi:10.1007/s00439-011-1054-1
31. Peterson RE, Edwards AC, Bacanu S-A, Dick DM, Kendler KS, Webb BT. The utility of empirically assigning ancestry groups in cross-population genetic studies of addiction. *Am J Addict*. 2017;26(5):494-501. doi:10.1111/ajad.12586
32. Yuan J, Xing H, Lamy AL, Lencz T, Pe'er I; Schizophrenia Working Group of the Psychiatric Genomics Consortium. Leveraging correlations between variants in polygenic risk scores to detect heterogeneity in GWAS cohorts. *PLoS Genet*. 2020; 16(9):e1009015. doi:10.1371/journal.pgen.1009015
33. Hamshere ML, Walters JTR, Smith R, et al; Schizophrenia Psychiatric Genome-wide Association Study Consortium; Wellcome Trust Case Control Consortium+; Wellcome Trust Case Control Consortium 2. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCAG8, and extensive replication of associations reported by the Schizophrenia PGC. *Mol Psychiatry*. 2013;18(6):708-712. doi:10.1038/mp.2012.67
34. Mortimer AM, Singh P, Shepherd CJ, Puthiyackal J. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. *Clin Schizophr Relat Psychoses*. 2010;4(1):49-55. doi:10.3371/CSRP.4.1.4
35. Suzuki T, Remington G, Mulsant BH, et al. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. *Psychiatry Res*. 2012;197(1-2):1-6. doi:10.1016/j.psychres.2012.02.013
36. Üçök A, Çıkrıklı U, Ergül C, et al. Correlates of clozapine use after a first episode of schizophrenia: results from a long-term prospective study. *CNS Drugs*. 2016;30(10):997-1006. doi:10.1007/s40263-016-0358-z
37. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience*. 2015;4(7):7. doi:10.1186/s13742-015-0047-8
38. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ*. 2003;326(7382):219. doi:10.1136/bmj.326.7382.219
39. Kontopantelis E, Sperrin M, Mamas MA, Buchan IE. Investigating heterogeneity of effects and associations using interaction terms. *J Clin Epidemiol*. 2018;93:79-83. doi:10.1016/j.jclinepi.2017.09.012
40. Bulik-Sullivan BK, Loh P-R, Finucane HK, et al; Schizophrenia Working Group of the Psychiatric Genomics Consortium. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet*. 2015; 47(3):291-295. doi:10.1038/ng.3211
41. Altshuler DM, Gibbs RA, Peltonen L, et al; International HapMap 3 Consortium. Integrating common and rare genetic variation in diverse human populations. *Nature*. 2010;467(7311):52-58. doi:10.1038/nature09298
42. Speed D, Balding DJ. SumHer better estimates the SNP heritability of complex traits from summary statistics. *Nat Genet*. 2019;51(2):277-284. doi:10.1038/s41588-018-0279-5
43. McCarthy S, Das S, Kretzschmar W, et al; Haplotype Reference Consortium. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet*. 2016;48(10):1279-1283. doi:10.1038/ng.3643
44. Rees E, Kirov G, Sanders A, et al; Wellcome Trust Case Control Consortium. Evidence that duplications of 22q11.2 protect against schizophrenia. *Mol Psychiatry*. 2014;19(1): 37-40. doi:10.1038/mp.2013.156
45. Choi SW, O'Reilly PF, PRSice-2: polygenic risk score software for biobank-scale data. *Gigascience*. 2019;8(7):giz082. doi:10.1093/gigascience/giz082
46. Ge T, Chen C-Y, Ni Y, Feng YA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nat Commun*. 2019;10(1):1776. doi:10.1038/s41467-019-09718-5
47. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Series B Stat Methodol*. 1995;57(1):289-300. doi:10.1111/j.2517-6161.1995.tb02031.x
48. Zheng X, Erzurumluoglu AM, Elsworth BL, et al; Early Genetics and Lifecourse Epidemiology (EAGLE) Eczema Consortium. LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics*. 2017;33(2):272-279. doi:10.1093/bioinformatics/btw613
49. Krapohl E, Euesden J, Zabaneh D, et al. Phenome-wide analysis of genome-wide polygenic scores. *Mol Psychiatry*. 2016;21(9):1188-1193. doi:10.1038/mp.2015.126
50. Niemi MEK, Martin HC, Rice DL, et al. Common genetic variants contribute to risk of rare severe neurodevelopmental disorders. *Nature*. 2018;562(7726):268-271. doi:10.1038/s41586-018-0566-4
51. Pain O, Glanville KP, Hagenars SP, et al. Evaluation of polygenic prediction methodology within a reference-standardized framework. *PLoS Genet*. 2021;17(5):e1009021. doi:10.1371/journal.pgen.1009021
52. de Bartolomeis A, Balletta R, Giordano S, Buonaguro EF, Latte G, Iasevoli F. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. *Psychiatry Res*. 2013;210(2): 387-395. doi:10.1016/j.psychres.2013.06.042
53. Frydecka D, Beszlej JA, Gościński P, Kiejna A, Misiak B. Profiling cognitive impairment in treatment-resistant schizophrenia patients. *Psychiatry Res*. 2016;235:133-138. doi:10.1016/j.psychres.2015.11.028
54. Zhang JP, Robinson D, Yu J, et al. Schizophrenia polygenic risk score as a predictor of antipsychotic efficacy in first-episode psychosis. *Am J Psychiatry*. 2019;176(1):21-28. doi:10.1176/appi.ajp.2018.17121363
55. Dwyer DB, Kalman JL, Budde M, et al. An investigation of psychosis subgroups with prognostic validation and exploration of genetic underpinnings: the Pscourse study. *JAMA Psychiatry*. 2020;77(5): 523-533. doi:10.1001/jamapsychiatry.2019.4910
56. Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. *Am J Psychiatry*. 2017;174(3):216-229. doi:10.1176/appi.ajp.2016.16050503
57. Wray NR, Lee SH, Kendler KS. Impact of diagnostic misclassification on estimation of genetic correlations using genome-wide genotypes. *Eur J Hum Genet*. 2012;20(6):668-674. doi:10.1038/ejhg.2011.257
58. Stone-Romero EF, Anderson LE. Relative power of moderated multiple regression and the comparison of subgroup correlation coefficients for detecting moderating effects. *J Appl Psychol*. 1994; 79(3):354-359. doi:10.1037/0021-9010.79.3.354
59. Gusev A, Ko A, Shi H, et al. Integrative approaches for large-scale transcriptome-wide association studies. *Nat Genet*. 2016;48(3):245-252. doi:10.1038/ng.3506
60. Zilhão NR, Olthof MC, Smit DJA, et al. Heritability of tic disorders: a twin-family study. *Psychol Med*. 2017;47(6):1085-1096. doi:10.1017/S0033291716002981
61. Wheeler AJ. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. *Ann Pharmacother*. 2008;42(6):852-860. doi:10.1345/aph.1K662